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Beta-Blocker Use Is Associated With Impaired Left Atrial Function in
Hypertension
Mayank Sardana, MBBS; Amer Ahmed Syed, MD; Zeba Hashmath, MD; Timothy S. Phan, BSBME, BSECE; Maheswara R. Koppula, MD;
Uzma Kewan, MD; Zoubair Ahmed, MD; Ravikantha Chandamuri, MD; Swapna Varakantam, MD; Ejaz Shah, MD; Ryan Gorz, BS;
Scott R. Akers, MD, PhD; Julio A. Chirinos, MD, PhD, FAHA
Background-—Impaired left atrial (LA) mechanical function is present in hypertension and likely contributes to various
complications, including atrial arrhythmias, stroke, and heart failure. Various antihypertensive drug classes exert differential effects
on central hemodynamics and left ventricular function. However, little is known about their effects on LA function.
Methods and Results-—We studied 212 subjects with hypertension and without heart failure or atrial ﬁbrillation. LA strain was
measured from cine steady-state free-precession cardiac MRI images using feature-tracking algorithms. In multivariable models
adjusted for age, sex, race, body mass index, blood pressure, diabetes mellitus, LA volume, left ventricular mass, and left ventricular
ejection fraction, beta-blocker use was associated with a lower total longitudinal strain (standardized b=0.21; P=0.008), and lower
LA expansion index (standardizedb=0.30; P<0.001), indicating impaired LA reservoir function. Beta-blocker usewas also associated
with a lower positive strain (standardizedb=0.19; P=0.012) and early diastolic strain rate (standardizedb=0.15;P=0.039), indicating
impaired LA conduit function. Finally, beta-blocker use was associated with a lower (less negative) late-diastolic strain (standardized
b=0.15; P=0.049), strain rate (standardized b=0.18; P=0.019), and a lower active LA emptying fraction (standardized b=0.27;
P<0.001), indicating impaired booster pump function. Use of other antihypertensive agents was not associated with LA function.
Conclusions-—Beta-blocker use is signiﬁcantly associated with impaired LA function in hypertension. This association could
underlie the increased risk of atrial ﬁbrillation and stroke seen with the use of beta-blockers (as opposed to other antihypertensive
agents) demonstrated in recent trials. ( J Am Heart Assoc. 2017;6:e005163. DOI: 10.1161/JAHA.116.005163.)
Key Words: angiotensin-converting enzyme inhibitors • b-adrenergic antagonists • hypertension • left atrium • magnetic
resonance imaging
A n increase in left atrial (LA) size in patients withhypertension has long been known to be associated
with worse cardiovascular morbidity and mortality.1,2 Over
the last decade, however, the prognostic importance of
phasic LA function, independent of LA size, has been
recognized.3 Compensatory changes in dynamic LA function
are seen early in the course of hypertension, even before left
ventricular hypertrophy (LVH) develops. Early in response to
the impaired left ventricular (LV) relaxation in hypertension,
the conduit function of the LA decreases, whereas its booster
function increases.4 However, with progression of hyperten-
sive heart disease, booster function also declines and is
associated with progression to heart failure5,6 and a poor
prognosis.7
Various classes of antihypertensive medications exert
differential effects on LV function and central hemodynamics.
Available trials, including the Losartan Intervention For End-
point reduction (LIFE) and the Anglo Scandinavian Cardiac
Outcomes Trial (ASCOT) [as well as the Conduit Artery Function
Evaluation (CAFE) substudy of ASCOT] have shown that, among
patients with hypertension, atenolol, when compared to
angiotensin receptor blockers (ARBs) and calcium-channel
blockers, is associated with lower LV mass regression,8 greater
central systolic pulse pressure relative to brachial pressures (ie,
lower pulse pressure ampliﬁcation),9 and a higher risk of
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stroke10 and atrial ﬁbrillation (AF).11 Unfortunately, little is
known about the effects of various antihypertensive agents on
LA function. In particular, an unfavorable effect of beta-blockers
on LA function is a plausiblemechanism for the increased risk of
AF and stroke associated with beta-blocker use, compared to
angiotensin receptor blockade.11 However, no data are avail-
able regarding the association between the use of beta-
blockers (or other antihypertensive drugs) and LA function.
In this study we aimed to assess whether the use of beta-
blockers, when compared to other antihypertensive agents, is
associated with impaired LA function, as assessed by
MRI-based measurements of atrial deformation and phasic
volumes.
Methods
Study Population
We enrolled a convenience clinical sample of 212 subjects with
history of hypertension at the Corporal Michael J. Crescenz VA
Medical Center. The protocol was approved by the Philadelphia
VA Medical Center Institutional Review Board, and written
informed consent was obtained from all participants. Key
exclusion criteria were as follows: (1) claustrophobia; (2)
presence of metallic objects or implanted medical devices
within the body; (3) AF at the time of enrollment; (4) conditions
that would make the study measurements less accurate or
unreliable (ie, arrhythmia affecting cardiac gating, inability to
perform an adequate breath hold for cardiac MRI acquisitions);
(5) heart failure with preserved or reduced ejection fraction
(EF); and (6) a left ventricular EF <50%.
Cine Imaging
Participants underwent a cardiac MRI examination to assess
LV structure and function, using a 1.5-Tesla (T) whole-body
MRI scanner (Avanto or Espree, Siemens, Malvern, PA)
equipped with a phased-array cardiac coil. LV volumes and
EF were determined using balanced steady-state free-preces-
sion (SSFP) cine imaging. Typical parameters were as follows:
TR=30.6 milliseconds; TE=1.3 milliseconds; phases=30; slice
thickness=8 mm; matrix size=1929192; and parallel image
(IPAT) factor=2. LV short-axis stack cine images were
manually traced at end-diastole and end-systole using
CMR42 software (Circle CVI, Calgary, AB, Canada). LV mass
(LVM) was computed as the difference between epicardial and
endocardial volumes, multiplied by myocardial density. LVM
was normalized for body height in meters raised to the
allometric power of 1.7.12
Left Atrial Longitudinal Strain and Volumetric
Analysis
All image analyses were performed using cvi42 image analysis
software (Circle Cardiovascular Imaging Inc, Calgary, AB,
Canada), blinded to the clinical characteristics of the study
subjects. Feature-tracking techniques for the measurement of
LA phasic strain have previously been described.13,14 LA
endocardial borders were manually traced in apical 2- and
4-chamber views using LV end-diastole as the point of
reference. An automated tracking algorithm was applied, and
the tracking of all atrial segments was conﬁrmed. Manual
A B
Figure 1. Representative example of atrial tissue tracking using cine SSFP-MRI images. A, The diastatic
left atrial phase, in which reference points are prescribed. B, The tracking of atrial tissue, shown at a
different phase of the cardiac cycle (see Video S1). The blue line represents the atrial wall contour. MRI
indicates magnetic resonance imaging; SSFP, steady-state free-precession.
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adjustments were performed as needed to optimize wall
tracking. An example of atrial wall tracking is shown in
Figure 1 and in Video S1.
Values of segmental deformation were exported and
further processed using custom software programmed in
Python (Python Software Foundation, Wilmington, DE). We
recomputed strain (deformation) and strain rate relative to the
diastatic LA length (rather than end-diastolic length), because
diastasis represents the length for LA tissue at the end of
atrial diastole (reference phase). As shown in Figure 2, strain
and strain rate were calculated in the reservoir (total
longitudinal strain), conduit (positive longitudinal strain and
early-diastolic strain rate), and booster (negative longitudinal
strain and late-diastolic strain rate) phases.14 Maximum
(LAMAX), minimum (LAMIN), and diastatic (LADIAS) LA volumes
were also measured. LA expansion index, passive LA emptying
fraction (LAEF), and active LAEF were calculated as volumetric
measures of reservoir, conduit, and booster phases, respec-
tively. LA expansion index was calculated as (LAMAXLAMIN)/
LAMIN, passive LAEF as (LAMAXLADIAS)/LAMAX, and active
LAEF as (LADIASLAMIN)/LAMAX.
Measurement of Central Blood Pressure
Arterial tonometry of the common carotid artery was
performed using a SphygmoCor EM3 device (AtCor Medical,
Sydney, Australia), equipped with a high-ﬁdelity Millar Appla-
nation tonometer (SPT-301; Millar Instruments, Houston, TX).
Tonometry was performed at the carotid artery in the supine
position immediately after the MRI. The carotid waveform was
calibrated with brachial diastolic and mean blood pressures
(which do not vary substantially along the arterial tree) and
were used as a direct surrogate of the central pressure
waveform. This approach does not require the use of a
generalized transfer function.
Statistical Methods
Continuous variables are presented as meanSD. Categorical
variables are presented as frequencies and percentages.
Various general characteristics and parameters of LA function
were compared between subjects who were receiving beta-
blockers versus those who were not. For continuous variables,
we used nonpaired t tests or Wilcoxon signed-rank tests as
appropriate. For categorical variables, we used chi-squared
tests. Multivariable linear regression was then performed to
determine the relationship between beta-blocker use (ex-
pressed as a binary variable) and various measures of LA
function. This relationship was assessed after adjustment for
potential confounders, including age, sex, race, body mass
index, systolic blood pressure, diastolic blood pressure,
diabetes mellitus, LA volume, LV mass, and LV EF. For easier
comparisons of the magnitude of the relationships of different
predictors, we present standardized regression coefﬁcients
(b). All probability values are 2-tailed. Statistical signiﬁcance
was deﬁned as a 2-tailed P<0.05. All statistical analyses were
performed using SPSS software (SPSS v24 for Mac; IBM SPSS
version 24, Chicago, IL).
Results
Baseline characteristics of study participants are presented
in Table 1. The average age was 6310 years; the majority
of subjects were males (94%), with similar proportions of
white and black participants. There was a moderate
prevalence of other cardiovascular risk factors, including
diabetes mellitus, hyperlipidemia, and smoking. Mean sys-
tolic and diastolic blood pressures were 14719 and
8412 mm Hg. The majority of participants were receiving
more than 1 antihypertensive agent at the time of
enrolment. There were no signiﬁcant differences in most
Figure 2. Representative Plots of Strain (A), and Strain rate (B), along with measures of reservoir, conduit
and booster pump function derived from strain and strain rate measurements. A, left atrial strain curve,
where total (reservoir, R), positive (conduit, C) and negative (booster pump, P) strain are demonstrated. B,
left atrial strain rate curve, where early diastolic (SR-E), late-diastolic (SR-A) and systolic (SR-S) strain rate
can be demonstrated. SR-E and SR-A represent left atrial conduit and booster pump function, respectively.
Note that atrial diastasis was used as the reference length for all strain/strain rate measurements.
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general characteristics between subjects who were receiving
beta-blockers and those who were not, except for a slightly
lower prevalence of smoking, a slightly lower LV EF, and a
signiﬁcantly greater prevalence of coronary artery disease
among beta-blocker users. Central hemodynamic data
(available in 176 subjects: 89 who used beta-blockers and
Table 1. Baseline Characteristics of Study Participants
Characteristics
Beta-blocker
Use (n=106)
No Beta-blocker
Use (n=106) P Value
Age, y 639 6210 0.41
Male sex 102 (96) 97 (91) 0.15
Race
White 49 (46) 51 (48) 0.49
Black 49 (46) 52 (49) 0.49
Body mass index, kg/m2 317 317 0.87
Systolic blood pressure, mm Hg 14819 14518 0.26
Diastolic blood pressure, mm Hg 8414 8411 0.46
Mean blood pressure, mm Hg 11717 11414 0.16
Pulse pressure, mm Hg 63.8 (13.6) 62.1 (14.4) 0.39
Current smoker 19 (18) 33 (31) 0.025
Diabetes mellitus 47 (44.3) 53 (50) 0.41
Hemoglobin A1C, % 6.51.3 6.41.6 0.61
eGFR, mL/(min1.73 m2) 8529 8630 0.80
Coronary artery disease 18 (17) 45 (42.5) <0.001
ACE inhibitor use 62 (59) 54 (51) 0.27
ARB use 13 (12) 10 (9) 0.51
Calcium-channel blocker use 36 (34) 39 (37) 0.67
Thiazide use 32 (30.2) 38 (36.2) 0.36
Spironolactone use 6 (5.7) 2 (1.9) 028
Specific beta-blocker used
Metoprolol 55 (51.9) — —
Carvedilol 28 (26.4) — —
Atenolol 13 (12.3) — —
Labetalol 4 (3.8) — —
Propranolol 4 (3.8) — —
Other 2 (1.9) — —
LVEF, % 608 628 0.035
LVM, g 15441 15138 0.54
LVM index, g/m1.7 5814 5814 0.89
Left atrial volume index, mL/m2 3314 3422 0.58
E to septal eʹ ratio 116 118 0.65
Resting heart rate, beats/min 61.911.1 65.211.9 0.053
Carotid augmentation index* 13.615.2 11.216.7 0.12
Carotid pulse pressure* 62.923.5 56.622.1 0.065
Carotid-to-brachial pressure amplification* 1.080.23 1.180.28 0.008
Values are meanSD or counts (percentages). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate; LVEF, left
ventricular ejection fraction; LVM, left ventricular mass.
*Data available in 176 subjects (89 who used beta-blockers and 87 who did not use beta-blockers).
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87 who did not) are also presented in Table 1. In contrast
to brachial pulse pressure, central pulse pressure tended to
be greater in beta-blocker users (62.9 mm Hg vs
56.6 mm Hg; P=0.065). Central-to-brachial pulse pressure
ampliﬁcation was signiﬁcantly lower in beta-blocker users
(1.08 vs 1.18, P=0.008).
Correlation of Left Atrial Parameters With
Antihypertensive Medications
Table 2 shows values of LA deformation measures and
volumes among subjects who were receiving beta-blockers
versus those who were not. Total longitudinal strain and LA
expansion index were signiﬁcantly lower in subjects receiving
beta-blockers (total longitudinal strain 24% vs 28%, P=0.005;
LA expansion index 1.10 vs 1.35, P<0.001, Figure 3).
Similarly, negative longitudinal strain (13% vs 15%,
P=0.008), late-diastolic strain rate (140%/s vs 163%/s,
P=0.008), and active LAEF (37% vs 42%, P=0.001) were lower
in subjects receiving beta-blockers. Less negative values of
late-diastolic strain and strain rate, present in subjects
receiving beta-blockers, indicate worse LA booster pump
function. Subjects receiving beta-blockers also demonstrated
lower values of negative early-diastolic strain rate (83%/s vs
99%/s, P=0.022), indicating impaired conduit function.
Table 3 shows the results of multivariable models in which
the relationship between beta-blocker use and LA function is
analyzed. In models that adjusted for adjusted for age, sex,
and race (Model 1, Table 3), beta-blocker use was consis-
tently associated with measures of impaired reservoir and
booster pump function, including lower total longitudinal
strain, LA expansion index, negative longitudinal strain, late-
diastolic strain rate, and active LAEF. In addition, beta-blocker
use was associated with a lower (less negative) early-diastolic
strain rate (standardized b=0.14: P=0.036) in these adjusted
models.
In multivariable models that adjusted for age, sex, race,
body mass index, blood pressure, the presence of diabetes
mellitus, and use of other antihypertensive agents (Model 2,
Table 3), beta-blocker use was associated with lower total
longitudinal strain (standardized b=0.21; P=0.005), and
lower LA expansion index (standardized b=0.27; P<0.0001),
indicating impaired LA reservoir function. Beta-blocker use
was also associated with a lower positive strain (standardized
b=0.16; P=0.024) and lower (ie, less negative) early-
diastolic strain rate (standardized b=0.17; P=0.016), indicat-
ing impaired LA conduit function. Finally, beta-blocker use
was associated with a lower (less negative) late-diastolic
strain (standardized b=0.16; P=0.028) and strain rate (stan-
dardized b=0.16; P=0.041), and lower active LAEF (standard-
ized b=0.26; P=0.001), indicating impaired booster pump
function. Angiotensin-converting enzyme inhibitor, angioten-
sin receptor blocker, calcium-channel blocker, thiazide, and
spironolactone use were not associated with LA function (not
shown).
With further multivariable adjustment for LV mass, LA
volume, and LV EF (Model 3, Table 3), the association of beta-
blockers with impaired LA reservoir and booster pump
function persisted. There was also a signiﬁcant association
between beta-blocker use and a lower positive longitudinal
strain (standardized b=0.19; P=0.012) and early-diastolic
strain rate (standardized b=0.15; P=0.039), which are
measures of LA conduit function.
Sensitivity Analyses
Given the signiﬁcant differences in the prevalence of
coronary artery disease between subjects who were taking
beta-blockers and those who were not, we performed
sensitivity analyses in which subjects with a history of
coronary artery disease were excluded (Table 4). As in the
overall study population, in these sensitivity analyses,
beta-blocker use was signiﬁcantly associated with LA
function. The numeric value of the point estimates for
standardized coefﬁcients in these analyses were, in general,
similar to or greater than the estimates in the overall
population.
Table 2. Left Atrial Parameters Among Subjects Receiving
Beta-blockers and Subjects Not Receiving Beta-blockers
Left Atrial Parameters
Beta-blocker
Use
No Beta-blocker
Use P Value
Reservoir function
Total longitudinal
strain, %
2410 2811 0.005
LA expansion index 1.100.41 1.350.43 <0.001
Conduit function
Positive longitudinal
strain, %
117 138 0.06
Early-diastolic strain
rate, %/s*
8349 9954 0.022
Passive LA ejection
fraction, %
228 239 0.13
Booster pump function
Negative longitudinal
strain, %*
136 156 0.008
Late-diastolic strain
rate, %/s*
14062 16366 0.008
Active LA emptying
fraction, %
3710 4210 0.001
LA indicates left atrium.
*Less negative value of diastolic strain and strain rate indicates worse LA function.
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Given the signiﬁcant differences in pulse pressure ampli-
ﬁcation between subjects who were receiving beta-blockers
and those who were not, we performed sensitivity analyses
regarding the association of beta-blocker use with LA function
among subjects with available carotid tonometry data
(Table 5). In this table Models 2 and 3 (multivariable models)
include adjustment for pulse pressure ampliﬁcation. It can be
observed that in models that adjusted for various confounders
(including measures of LV structure and function and central-
to-brachial pulse pressure ampliﬁcation, Model 3), beta-
blocker use remained predictive of LA function, suggesting
that the observed relationship between beta-blocker use and
parameters of LA function is, at least in part, independent of
the effect of beta-blockers on central pressures.
Figure 3. Bar graphs comparing various left atrial parameters in participants on beta-blockers to
participants not on beta-blockers. LA indicates left atrium; LAEF, left atrial emptying fraction; SR, strain
rate. Absolute values for early-diastolic strain rate, negative longitudinal strain, and late-diastolic strain
rate are presented for the ease of direct comparison between the groups. Error bars represent standard
errors of the mean.
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Discussion
We demonstrate for the ﬁrst time that among hypertensive
subjects without heart failure and AF, beta-blocker use is
signiﬁcantly associated with impaired LA reservoir, conduit,
and booster pump function. This association may underlie the
increased risk of atrial arrhythmia and stroke that has been
observed with the use of these agents in patients with
hypertension.11
Left Atrial Remodeling in Hypertension
Structural and functional remodeling of the LA is seen early in
the course of hypertension. In a cross-sectional study using
2-dimensional echocardiographic volumes and spectral Dop-
pler, Eshoo et al4 found that reservoir and conduit LA
functions were decreased, whereas booster function was
increased, among participants with untreated mild hyperten-
sion compared to healthy volunteers. In that study LA volumes
Table 3. Unadjusted and Adjusted Standardized Regression Coefﬁcients for the Association of Left Atrial Measures With Beta-
blocker Use
Left Atrial Parameters
Model 1 Estimated Standardized
b Coefﬁcient (P Value)
Model 2 Estimated Standardized
b Coefﬁcient (P Value)
Model 3 Estimated Standardized
b Coefﬁcient (P Value)
Reservoir function
Total longitudinal strain 0.18 (0.009) 0.21 (0.005) 0.21 (0.006)
LA expansion index 0.26 (<0.001) 0.27 (<0.001) 0.30 (<0.001)
Conduit function
Positive longitudinal strain 0.11 (0.094) 0.16 (0.024) 0.19 (0.012)
Early-diastolic strain rate* 0.14 (0.036) 0.17 (0.016) 0.15 (0.039)
Passive LA ejection fraction 0.08 (0.235) 0.10 (0.140) 0.08 (0.26)
Booster pump function
Negative longitudinal strain* 0.18 (0.010) 0.16 (0.028) 0.15 (0.049)
Late-diastolic strain rate* 0.18 (0.009) 0.16 (0.041) 0.18 (0.019)
Active LA emptying fraction 0.23 (0.001) 0.26 (0.001) 0.27 (<0.001)
Model 1: adjusted for age, sex, and race. Model 2: adjusted for variables in Model 1 plus body mass index, systolic and diastolic blood pressure, presence of diabetes mellitus, coronary
artery disease, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, spironolactone, and diuretics. Model 3: adjusted for variables in
Model 2 plus LA volume, left ventricular mass, and left ventricular ejection fraction. LA indicates left atrium.
*Positive coefﬁcients in diastolic strain and strain rate indicate “less negative values” and therefore worse left atrial function.
Table 4. Sensitivity Analyses Showing Unadjusted and Adjusted Standardized Regression Coefﬁcients for the Association of Left
Atrial Measures With Beta-blocker Use, After Excluding Subjects With CAD (nincluded=146)
Left Atrial Parameters
Model 1 Estimated Standardized
b Coefﬁcient (P Value)
Model 2 Estimated Standardized
b Coefﬁcient (P Value)
Model 3 Estimated Standardized
b Coefﬁcient (P Value)
Reservoir function
Total longitudinal strain 0.22 (0.007) 0.28 (0.002) 0.29 (0.002)
LA expansion index 0.27 (0.001) 0.34 (<0.001) 0.32 (<0.001)
Conduit function
Positive longitudinal strain 0.14 (0.078) 0.21 (0.02) 0.27 (0.003)
Early-diastolic strain rate* 0.21 (0.005) 0.26 (0.002) 0.25 (0.004)
Passive LA ejection fraction 0.08 (0.28) 0.10 (0.205) 0.09 (0.28)
Booster pump function
Negative longitudinal strain* 0.21 (0.010) 0.23 (0.01) 0.19 (0.036)
Late-diastolic strain rate* 0.23 (0.006) 0.24 (0.008) 0.26 (0.004)
Active LA emptying fraction 0.23 (0.001) 0.29 (0.002) 0.28 (<0.001)
Model 1: adjusted for age, sex, and race. Model 2: adjusted for variables in Model 1 plus body mass index, systolic and diastolic blood pressure, presence of diabetes mellitus, use of
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, spironolactone, and diuretics. Model 3: adjusted for variables in Model 2 plus left atrial
volume, left ventricular mass, and left ventricular ejection fraction. LA indicates left atrium.
*Positive coefﬁcients in diastolic strain and strain rate indicate “less negative values” and therefore worse left atrial function.
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were increased in association with the degree of LVH,
indicating the presence of structural remodeling. As hyper-
tensive heart disease progresses, booster and booster reserve
function (an index of the degree of booster function increase
with exercise) also decrease.5,6 Structural and functional
remodeling of LA have been associated with an increased risk
of cardiovascular morbidity and mortality in population-based
studies.1,3 In the Dallas Heart Study, LAEF (an indicator of LA
reservoir function) predicted mortality even after adjustment
for LA volume index, suggesting the prognostic importance of
functional remodeling independent of LA structure.15 In a
cohort study of participants with chronic hypertension,
Kaminski et al showed that a decrease in active LAEF (an
indicator of LA booster pump function) was independently
associated with all-cause mortality and major adverse cardiac
events.7
Beta-blockers, Hypertension, and Left Atrial
Parameters
To the best of our knowledge, no prior study has examined the
relationship between the use of speciﬁc antihypertensive
agents and measures of LA mechanical function. We used
cardiac MRI-based LA volume measurements, along with
feature tracking–based assessment of phasic atrial wall
longitudinal deformation.14 We utilized these modalities to
measure LA volumes, LA strain, and strain rate during various
phases. We found that, in contrast to other antihypertensive
agents (such as calcium-channel blockers, angiotensin-
converting enzyme [ACE] inhibitors, and ARBs), beta-blocker
use was consistently associated with impaired reservoir,
conduit, and booster pump LA function.
Beta-blocker use has been associated with an increased
risk of cardiovascular morbidity and mortality.16,17 Further-
more, an atenolol-based strategy, when compared to a
losartan-based strategy, was associated with a higher risk of
AF and stroke10,11 in the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) trial. In this randomized
trial participants in the atenolol-based group also showed
less regression of LA and LV structural remodeling.8,18
Although we found depressed LA phasic function (a marker
of LA functional remodeling) in participants using beta-
blockers, there was no difference in LV mass and LA
volumes (a marker of structural remodeling). This might be
because, unlike LIFE trial participants, nearly two-thirds of
the participants who used beta-blockers in our study were
also receiving an ACE inhibitor or ARB. Interestingly, in a
cohort study by Kaminski et al, a signiﬁcantly higher
proportion of participants with depressed active LAEF were
taking beta-blockers compared to those with higher LAEF
(71% vs 57%, P=0.04). However, this association was not
explored further in this study. In our comprehensive
evaluation of LA function with use of volumetric and
strain-based parameters, we found that beta-blocker use
was associated with depressed LA function in all 3 domains
(reservoir, conduit, and booster), and this association was
consistently demonstrated with various measures of LA
function in each domain.
Table 5. Sensitivity Analyses Showing Unadjusted and Adjusted Standardized Regression Coefﬁcients for the Association of
Measures of Left Atrial Measures With Beta-blocker Use, Among Subjects With Available Carotid Tonometry Data (n Included=176)
Left Atrial Parameters
Model 1 Estimated Standardized
b Coefﬁcient (P Value)
Model 2 Estimated Standardized
b Coefﬁcient (P Value)
Model 3 Estimated Standardized
b Coefﬁcient (P Value)
Reservoir function
Total longitudinal strain 0.15 (0.052) 0.19 (0.022) 0.20 (0.017)
LA expansion index 0.23 (0.003) 0.25 (0.003) 0.24 (0.004)
Conduit function
Positive longitudinal strain 0.12 (0.092) 0.15 (0.062) 0.18 (0.028)
Early-diastolic strain rate* 0.18 (0.012) 0.20 (0.01) 0.19 (0.02)
Passive LA ejection fraction 0.12 (0.09) 0.10 (0.18) 0.07 (0.36)
Booster pump function
Negative longitudinal strain* 0.11 (0.162) 0.15 (0.073) 0.19 (0.036)
Late-diastolic strain rate* 0.13 (0.10) 0.17 (0.055) 0.19 (0.029)
Active LA emptying fraction 0.17 (0.03) 0.20 (0.022) 0.15 (0.093)
Model 1: adjusted for age, sex, and race. Model 2: adjusted for variables in Model 1 plus central-to-brachial pulse pressure ampliﬁcation, body mass index, systolic and diastolic blood
pressure, presence of diabetes mellitus, coronary artery disease, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, spironolactone,
and diuretics. Model 3: adjusted for variables in Model 2 plus LA volume, left ventricular mass, and left ventricular ejection fraction. LA indicates left atrium.
*Positive coefﬁcients in diastolic strain and strain rate indicate “less negative values” and therefore worse LA function.
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Potential mechanisms linking beta-blocker use with atrial
dysfunction may include any of the following factors, alone or
in combination: (1) direct negative inotropic effects of beta-
blockers on the LA myocardium19; (2) LA dysfunction
secondary to negative inotropic or lusitropic effects of beta-
blockers on the LV20,21; and (3) worsening LA-LV-aortic
coupling due to the effects of beta-blockers on central
hemodynamics. Although we observed a slightly decreased
LVEF in participants using beta-blockers (608% vs 628%,
P<0.035), the association between LA function and beta-
blocker use persisted after adjustment for LVEF. Previous
studies indicate that central pulsatile hemodynamics is
associated with LA remodeling and dysfunction in hyperten-
sion.22,23 In the CAFE study,9 a prospective substudy of
ASCOT, the use of atenolol-based regimens was associated
with higher central systolic and pulse pressure despite similar
reduction in peripheral blood pressure when compared to
amlodipine-based regimens. In the LIFE trial,24 higher pulse
pressure was observed in the atenolol-based group when
compared to the losartan-based group, and this independently
predicted increased risk of cardiovascular morbidity and
mortality in these participants. We found that hypertensive
subjects who were receiving beta-blockers demonstrated a
lower pulse pressure ampliﬁcation, indicating greater central
pulse pressure for any given level of brachial pulse pressure.
Interestingly, in our sensitivity analyses examining the rela-
tionship between beta-blocker use and LA function among
subjects with available central pressure data (Table 4), beta-
blocker use remained predictive of measures of LA function
after adjustment for various confounders, including carotid-to-
brachial pulse pressure ampliﬁcation. This indicates that the
effects of beta-blockers on LA function are, at least in part,
independent on their effects on central pulse pressure.
Strengths and Limitations
To the best of our knowledge, this is the ﬁrst study to evaluate
the relationship between the use of different antihypertensive
agents and phasic LA function. An additional strength of our
study is the use of cardiac MRI, which provides superior
quantitative data about volumes and chamber function.
Furthermore, we used novel tissue-tracking algorithms to
assess tissue strain (deformation), a more direct measure of
myocardial function. The high consistency of our results with
various functional LA indices, and with multiple adjustments
for potential confounders, adds conﬁdence to our results.
However, these results should be interpreted in the context of
the study limitations. Although the observed relationships
with beta-blocker use were highly consistent and statistically
signiﬁcant, the magnitude of the association in multivariable
analyses was modest to moderate. However, this may be due
to the multiple potential factors (other than beta-blocker use)
that can have an impact on LA function. Residual confounding
cannot be excluded, and our study does not ﬁrmly establish a
cause-effect relationship because of its cross-sectional
nature. Many patients were receiving combination therapy
with various agents and various doses; it is possible that
concomitant therapy may have confounded the association
between beta-blocker use and LA function. However, this is
unlikely given that there was no evidence of an association
between other classes of antihypertensives and LA function
parameters in the sample. In addition, we adjusted for
concomitant drug class. More detailed modeling of the
potential confounding effects of speciﬁc drugs in each class
and at different dosages was not possible due to the
moderate sample size. Another limitation is that we did not
account for the duration of hypertension or of drug therapy
with various agents. Interestingly, because beta-blockers were
historically a ﬁrst-line medication, beta-blocker use could
reﬂect a longer duration of hypertension, which in turn would
reﬂect greater negative effects of hypertension on LA
function. However, we note that adjustment for other
structural factors (including LV mass, end-diastolic volume,
and EF) did not attenuate the observed associations.
Furthermore, we utilized a convenience sample to recruit
our study participants at our VA Medical Center, which limits
the generalizability of the ﬁndings. Our study population was
therefore composed predominantly of males. Although we
included sex as a covariate in multivariable regression models,
further validation of our observations in samples that include
a larger number of women should be performed. Finally, there
was a signiﬁcant difference in the prevalence of coronary
artery disease between the 2 groups. Although we performed
sensitivity analyses to address these differences, residual
confounding cannot be fully excluded.
Conclusions
In summary, in this cross-sectional analysis of participants
with chronic hypertension, we found a signiﬁcant association
of beta-blocker use with impaired reservoir, conduit, and
booster pump LA function when compared to other antihy-
pertensive agents. This association could underlie the
increased risk of AF and stroke seen with the use of beta-
blockers (as opposed to other antihypertensive agents) in
recent trials.
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